Annexon, Inc. financial data

Symbol
ANNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.65K % +44.3%
Debt-to-equity 17.5 % -25%
Return On Equity -44.7 % +30.5%
Return On Assets -38 % +27.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.6M shares +1.06%
Common Stock, Shares, Outstanding 78.4M shares +64.2%
Entity Public Float 121M USD -3.36%
Common Stock, Value, Issued 106K USD +100%
Weighted Average Number of Shares Outstanding, Basic 130M shares +73%
Weighted Average Number of Shares Outstanding, Diluted 130M shares +73%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 97.1M USD -18.4%
General and Administrative Expense 29.8M USD -8.9%
Operating Income (Loss) -127M USD +16.3%
Net Income (Loss) Attributable to Parent -115M USD +19.6%
Earnings Per Share, Basic -1.22 USD/shares +28.7%
Earnings Per Share, Diluted -1.22 USD/shares +28.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 157M USD +38.5%
Cash, Cash Equivalents, and Short-term Investments 369M USD +91.1%
Other Assets, Current 23K USD -86.1%
Assets, Current 374M USD +89.3%
Property, Plant and Equipment, Net 13.7M USD -13.4%
Operating Lease, Right-of-Use Asset 17.4M USD -6.5%
Other Assets, Noncurrent 361K USD +2908%
Assets 406M USD +74.3%
Accounts Payable, Current 4.13M USD -42.4%
Accrued Liabilities, Current 10.7M USD +19%
Liabilities, Current 17.1M USD -4.15%
Operating Lease, Liability, Noncurrent 27.9M USD -8.36%
Liabilities 45M USD -6.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -89K USD +48%
Retained Earnings (Accumulated Deficit) -627M USD -22.5%
Stockholders' Equity Attributable to Parent 361M USD +95.5%
Liabilities and Equity 406M USD +74.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.3M USD +14.3%
Net Cash Provided by (Used in) Financing Activities 32.4M USD +84.4%
Net Cash Provided by (Used in) Investing Activities -77.3M USD -496%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 78.4M shares +64.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 158M USD +38.1%
Deferred Tax Assets, Valuation Allowance 131M USD +29.9%
Deferred Tax Assets, Gross 137M USD +27.7%
Operating Lease, Liability 30.2M USD -5.66%
Depreciation 2.1M USD 0%
Payments to Acquire Property, Plant, and Equipment 137K USD -97.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -115M USD +19.5%
Lessee, Operating Lease, Liability, to be Paid 40.8M USD -9.77%
Property, Plant and Equipment, Gross 19.8M USD +0.11%
Operating Lease, Liability, Current 2.35M USD +45.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.24M USD +3.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.07M USD +3.52%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.6M USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.43M USD +3.49%
Deferred Tax Assets, Operating Loss Carryforwards 71M USD +11.7%
Unrecognized Tax Benefits 3.97M USD +45.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.43M USD +3.49%
Additional Paid in Capital 988M USD +41.8%
Depreciation, Depletion and Amortization 538K USD +0.37%
Deferred Tax Assets, Net of Valuation Allowance 5.57M USD -8.54%
Share-based Payment Arrangement, Expense 18.5M USD -2.59%